Published within
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
AstraZeneca's [AZN.L] Iressa was billed as one of a new class of anti-tumor agents that would revolutionize the treatment of lung cancer. However, to date the drug has been disappointing and approvals continue to be for third-line treatment. If Iressa is to reach blockbuster status, it must reach patients as a first line therapy.
Published By Datamonitor
|
05 Jan 2004 |
|
CommentWire
|
GW Pharmaceuticals [GWP.L] and Bayer Healthcare [BAY.F] have submitted a New Drug Submission for Sativex, a cannabis-based medicine for the symptomatic treatment of multiple sclerosis (MS) and neuropathic pain, to Health Canada. This move will help generate optimism regarding Sativex, offering renewed hope for manufacturers and patients alike.
Published By Datamonitor
|
13 May 2004 |
|
CommentWire
|
Apotex and Dr Reddy's have been challenging Sanofi [SNY] and Bristol-Myers Squibb (BMS) [BMY] over a Plavix patent concerning a 'parent molecule', which expires in 2011. However, the fact that the challenge was rejected in Canada is a positive outcome for Sanofi and BMS and indicates that they could also win the case in the more important US market.
Published By Datamonitor
|
23 Mar 2005 |
|
CommentWire
|
Cardiome Pharma has revealed that its phase II study investigating the safety and efficacy of oxypurinol in heart failure patients failed to meet both the primary and secondary endpoints, sparking debate over oxypurinol's future. Indeed, it looks like Cardiome may now have to put all of its eggs into one basket, depending on its other pipeline drug, RSD1235.
Published By Datamonitor
|
17 Aug 2005 |
|
CommentWire
|
Canadian regulators' approval of a phase III trial examining Multikine in head and neck cancer is a clear fillip for manufacturer Cel-Sci, as the drug is the firm's lead product. However, Multikine is still likely struggle to compete with rival product Erbitux, which is in late-stage development and has already demonstrated a survival advantage in head and neck cancer.
Published By Datamonitor
|
24 Aug 2005 |
|
CommentWire
|
Canadian regulators have agreed to allow Shire's ADHD drug Adderall XR to return to the market following its temporary withdrawal earlier this year. This is good news for Shire as reinstatement of Adderall XR in Canada will help to re-establish both the drug's reputation and its share of the Canadian ADHD market. However, looking at the outlook for the drug in a wider context, it is no panacea.
Published By Datamonitor
|
26 Aug 2005 |
|
CommentWire
|
Migenix' CEO recently announced the company's plans to initiate a clinical combination clinical trial with celgosivir in treatment-naive hepatitis C patients. While this is further good news for the experimental drug's development, direct HCV inhibitors are currently perceived as the most promising developmental drug class, and competition in the hepatitis C market is thus expected to be fierce.
Published By Datamonitor
|
25 Jan 2006 |
|
CommentWire
|
Canadian generics firm Apotex has received an approval from the FDA to launch a generic version of Sanofi-Aventis and Bristol-Myers Squibb's blockbuster heart drug Plavix. This is bad, although expected, news for the two pharma giants, which both need to stave off such generic threats. However, the companies are not going down without a fight, as Sanofi-Aventis' patent infringement filing shows.
Published By Datamonitor
|
27 Jan 2006 |
|
CommentWire
|
Sanofi-Aventis and Bristol-Myers Squibb have reached an agreement to settle a patent infringement suit with Canadian generics maker Apotex over the anti-platelet agent Plavix. As well as enabling the companies to avoid court proceedings, the settlement should delay the generic threat to Plavix - a possibility the pharma heavyweights' investors have already embraced judging by share price surges.
Published By Datamonitor
|
23 Mar 2006 |
|
CommentWire
|
Toronto-based Transition Therapeutics has posted positive 12-week data from a phase I/II trial investigating the safety and efficacy of HCV-IET in hepatitis C non-responders. However, although its results to date look promising, the drug candidate looks set to face stiff competition from other pipeline products, several of which appear to have a head-start.
Published By Datamonitor
|
08 Aug 2006 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.